Infanrix (diphtheria and tetanus toxoids and acellular pertussis vaccine adsorbed) / GSK - LARVOL DELTA

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (clinicaltrials.gov) - P4 | N=27945 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Aug 2025 ➔ Aug 2028

Trial completion date • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

A Preliminary Study to Evaluate the Immune Response to a Booster Dose of the Adult Tetanus-Diphtheria Vaccine (Td) Available in Iran. (PubMed, Iran J Pharm Res) - "The seroconversion rate of the Iranian Td vaccine was comparable to other common tetanus vaccines, including Tenivac®, Adacel®, Infanrix®, Tetavax®, and Vacteta®. The proportion of suitable candidates for plasma donation, based on minimum (2 IU/mL) and maximum (10 IU/mL) anti-tetanus toxoid antibody titers, was 100% and 45%, respectively."

Journal • Infectious Disease • Pain • Tetanus

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (clinicaltrials.gov) - P2 | N=78 | Recruiting | Sponsor: Mayo Clinic | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Sarcoma • Solid Tumor

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (clinicaltrials.gov) - P4 | N=28000 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial (clinicaltrials.gov) - P2 | N=78 | Not yet recruiting | Sponsor: Mayo Clinic

Metastases • New P2 trial • Fallopian Tube Cancer • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Sarcoma • Solid Tumor

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (clinicaltrials.gov) - P4 | N=5000 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Enrolling by invitation ➔ Active, not recruiting

Enrollment closed • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology • Solid Tumor

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) - P1/2 | N=550 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Jul 2024 ➔ Apr 2025 | Trial primary completion date: Jul 2024 ➔ Apr 2025

Trial completion date • Trial primary completion date

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study (clinicaltrials.gov) - P4 | N=25000 | Enrolling by invitation | Sponsor: National Cancer Institute (NCI) | Active, not recruiting ➔ Enrolling by invitation | Trial completion date: Aug 2024 ➔ Aug 2025 | Trial primary completion date: Aug 2024 ➔ Aug 2025

Enrollment open • Trial completion date • Trial primary completion date • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) - P1/2 | N=550 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Apr 2024 ➔ Jul 2024 | Trial primary completion date: Apr 2024 ➔ Jul 2024

Trial completion date • Trial primary completion date

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (clinicaltrials.gov) - P4 | N=5000 | Enrolling by invitation | Sponsor: National Cancer Institute (NCI) | Not yet recruiting ➔ Enrolling by invitation

Enrollment open • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial (clinicaltrials.gov) - P4 | N=5000 | Not yet recruiting | Sponsor: National Cancer Institute (NCI)

New P4 trial • Cervical Cancer • Infectious Disease • Oncology • Solid Tumor

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) - P1/2; N=550; Recruiting; Sponsor: GlaxoSmithKline; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • PCR

A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (clinicaltrials.gov) - P1/2; N=550; Not yet recruiting; Sponsor: GlaxoSmithKline

Clinical • New P1/2 trial • PCR